In experimental sarcoma and glioma models, ICI efficacy depends not only on CD8+ , but also on CD4+ T cells [20, 21], and it has been shown that this also requires activity of antigen-specific CD4+ T cells in tumors with expression of MHC class II-restricted neoantigens [22]. This evidence concerns the gene CD8A and central nervous system cancer.